Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | F12 | P00748 | 1/20 | 0.46 |
| ▸ | F7 | P08709 | 1/20 | 0.46 |
| ▸ | F3 | P13726 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | C1S | P09871 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.39 |
| ▸ | HTR3B | O95264 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.39 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7361311 | 0.86 | NPSR1 (0.43) | ALDH1A1F2F10F12F7 | |
| SCHEMBL3073692 | 0.86 | ALDH1A1 (0.45) | ALDH1A1F2F10F12F7 | |
| SCHEMBL11134255 | 0.86 | ALDH1A1 (0.56) | ALDH1A1F2F10F12F7 | |
| Hydrochloric Acid SCHEMBL28482173 | 0.84 | ALDH1A1 (0.43) | ALDH1A1F2F10F12F7 | |
| SCHEMBL6694014 | 0.81 | NPSR1 (0.43) | ALDH1A1F2F10F12F7 | |
| SCHEMBL6687559 | 0.81 | ALDH1A1 (0.53) | ALDH1A1F2F10F12F7 | |
| SCHEMBL7075852 | 0.81 | TDP1 (0.49) | ALDH1A1F2F10F12F7 | |
| SCHEMBL1740828 | 0.80 | ALDH1A1 (0.44) | ALDH1A1F2KMT2APRSS1MEN1 | |
| SCHEMBL6701182 | 0.80 | NPSR1 (0.42) | ALDH1A1F2F10F12F7 | |
| SCHEMBL6698602 | 0.80 | NPSR1 (0.42) | ALDH1A1F2F10F12F7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0506207-B1 | Pharmaceutical vehicles for reducing transdermal flux | ACCESS PHARMA INC (US) | 1999-11-17 | — | — | EP | claimed |
| EP-4180482-B1 | MOISTURE-CURABLE COMPOSITION | NITTO KASEI CO LTD (JP) | 2025-12-03 | — | — | EP | disclosed |
| US-12479869-B2 | Curing catalyst used for curing of polymer, method for producing same, moisture-curable composition, and method for producing cured product | NITTO KASEI CO., LTD. (JP) | 2025-11-25 | — | — | US | disclosed |
| EP-4174053-B1 | CURING CATALYST USED FOR CURING OF POLYMER, METHOD FOR PRODUCING SAME, MOISTURE-CURABLE COMPOSITION, AND METHOD FOR PRODUCING CURED PRODUCT | NITTO KASEI CO LTD (JP) | 2025-11-19 | — | — | EP | disclosed |
| EP-4569023-A1 | COMBINATION OF CATALYTIC COMPONENTS | PolyU GmbH (DE) | 2025-06-18 | — | — | EP | disclosed |
| CN-115516041-B | Curing catalyst for curing polymer, method for producing same, moisture-curable composition, and method for producing cured product | 日东化成株式会社 | 2024-06-28 | — | — | CN | disclosed |
| WO-2024033348-A1 | COMBINATION OF CATALYTIC COMPONENTS | POLYU GMBH (DE) | 2024-02-15 | — | — | WO | disclosed |
| EP-4321573-A1 | COMBINATION OF CATALYTIC COMPONENTS | PolyU GmbH (DE) | 2024-02-14 | — | — | EP | disclosed |
| US-20230234976-A1 | CURING CATALYST USED FOR CURING OF POLYMER, METHOD FOR PRODUCING SAME, MOISTURE-CURABLE COMPOSITION, AND METHOD FOR PRODUCING CURED PRODUCT | NITTO KASEI CO., LTD. (JP) | 2023-07-27 | — | — | US | disclosed |
| EP-4180482-A1 | MOISTURE-CURABLE COMPOSITION | Nitto Kasei Co., Ltd. (JP) | 2023-05-17 | — | — | EP | disclosed |
| CN-104045976-A | Resin composition | AJINOMOTO KK | 2014-09-17 | — | — | CN | disclosed |
| WO-2011118818-A8 | AMIDINOANILINE DERIVATIVE | 味の素株式会社 (JP) | 2012-01-26 | — | — | WO | disclosed |
| EP-2388297-A1 | CURABLE COMPOSITION AND CURED OBJECT FORMED THEREFROM | Kaneka Corporation (JP) | 2011-11-23 | — | — | EP | disclosed |
| EP-2267083-A1 | CURABLE COMPOSITION AND CURED MATERIAL | Kaneka Corporation (JP) | 2010-12-29 | — | — | EP | disclosed |
| EP-1988127-B1 | CURABLE COMPOSITION | KANEKA CORP (JP) | 2010-12-15 | — | — | EP | disclosed |
| EP-1985666-B1 | CURABLE COMPOSITION | KANEKA CORP (JP) | 2010-12-15 | — | — | EP | disclosed |
| US-20090182099-A1 | CURABLE COMPOSITION | KANEKA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090182091-A1 | CURABLE COMPOSITION | KANEKA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1988127-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2008-11-05 | — | — | EP | disclosed |
| EP-1985666-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479869-B2 | Curing catalyst used for curing of polymer, method for producing same, moisture-curable composition, and method for producing cured product | KDM2B, SETDB1, ASH2L | ALDH1A1 615/4885F2 2662/4885F10 3114/4885 |
| US-20230234976-A1 | CURING CATALYST USED FOR CURING OF POLYMER, METHOD FOR PRODUCING SAME, MOISTURE-CURABLE COMPOSITION, AND METHOD FOR PRODUCING CURED PRODUCT | KDM2B, SETDB1, ASH2L | ALDH1A1 615/4885F2 2662/4885F10 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.